SCHEMBL3598536

SCHEMBL3598536

COC(CSc1cc(F)ccc1Br)OC

nearest known ligand 0.36

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36
AMY1A P0DUB6 1/20 0.33
PKM P14618 1/20 0.30
ACHE P22303 1/20 0.30
HTR2A P28223 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31358088 0.87 MAOA (0.36) MAOAMAOBAMY1APKMACHE
SCHEMBL6597582 0.84 MAOA (0.34) MAOAMAOB
SCHEMBL3595820 0.81 HPGD (0.36) MAOAMAOBHTR2A
SCHEMBL5153339 0.76 MAOA (0.61) MAOAMAOB
SCHEMBL31728477 0.72 MAOA (0.34) MAOAMAOBPKM
SCHEMBL6595284 0.72 MAOA (0.34) MAOAMAOBPKM
SCHEMBL1775568 0.72 NPC1 (0.37) MAOAMAOB
SCHEMBL7497565 0.71
SCHEMBL15390878 0.71 MAOA (0.36) MAOAMAOBAMY1AHTR2A
SCHEMBL30128237 0.71 MAOA (0.36) MAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1553074-B1 FUSED BENZENE DERIVATIVE AND USE TAKEDA PHARMACEUTICAL (JP) 2014-06-18 EP disclosed
US-7649001-B2 Fused benzene derivative and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-19 US disclosed
US-20060106067-A1 Fused benzene derivative and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-05-18 US disclosed
EP-1553074-A1 FUSED BENZENE DERIVATIVE AND USE Takeda Pharmaceutical Company Limited (JP) 2005-07-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106067-A1 Fused benzene derivative and use AR, NR5A1, CBR3 MAOA 2120/4885MAOB 959/4885AMY1A 4158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.